Skip to main content

The petitioners have filed the present petition, inter alia, praying for prohibition/ban of the import, manufacture, sale, distribution and export of spurious drugs manufactured by Respondent No. 3 (Lucius Pharmaceuticals) including Lucicriz, Lucisun, Luciax and Lucipalb.

The Petitioners are manufacturers of certain drugs used for the treatment of cancer. The Petitioners allege that spurious drugs manufactured by Respondent No. 3 are being marketed and sold in India, without the requisite licenses issued by the Drugs Controller. Respondent No. 3 is a fictitious company with an untraceable address in Sri Lanka and is manufacturing and selling infringing life-saving drugs in India. Respondent No. 3’s products are spurious, misbranded and unlicensed and claim to treat serious medical conditions like cancer. In Pfizer’s writ petition against the Government and the entity Lucius Pharmaceuticals, the Hon’ble High Court of Delhi has observed the following:

  1. The Government and the Drugs Controller’s office (Respondent No. 1 and 2) confirmed that Lucius’s drugs (Lucicriz – Crizotinib, Lucisun – Sunitinib, Luciax – Axitinib and Lucipalb – Palbociclib) are spurious and no permission for sale of the said drugs has been granted by the Central Drugs Standards Control Organization (CDSCO);
  2. The Government stated that the action for preventing spurious drugs is required to be taken by the concerned State Governments and if the Petitioners provide the information as to where such drugs are being sold, CDSCO shall coordinate with the State Governments to take appropriate action;
  3. The Court held that the import and sale of Respondent No. 3’s drugs are illegal;
  4. The Court has asked the Petitioners to provide the necessary information regarding the spurious drugs to Respondent No. 1 and 2 and to file complaints before the State authorities in this regard.

The Hon’ble Court further directed Respondent No. 1 to take necessary legal action in coordination with the respective State Governments. The Court has also passed directions to the effect that if any complaints are made regarding the drugs in question, the concerned State authorities shall take appropriate steps in accordance with the law to prevent the sale of the spurious drugs and further to prosecute the offenders to the fullest extent of the law as expeditiously as possible.

The Hon’ble Delhi High Court noted that these drugs (manufactured and sold by M/s Lucius Pharmaceuticals) are spurious and their import and sale in India is illegal.

Team Anand and Anand: Pravin Anand, Tusha Malhotra and Rashi Punia.

Most Recent

News & Insights

VIEW ALL
News & Updates, Thought Leadership
Jan 15, 2026

First published by Lexology. Authors: Safir Anand, Mudit Kaushik and Sehr Anand The handling of price sensitive corporate information has become increasingly

The Regulatory Cost of Informal Digital Disclosures
News & Updates
Jan 02, 2026

First published by Lexology. Authors: Pravin Anand, Saif Khan, Shobhit Agarwal and Prajjwal Kushwaha A. Background B. Legal Issues Addressed C. Directions

Landmark Ruling On Domain Name Fraud and Systematic Reforms in Digital Commerce
Thought Leadership
Jan 01, 2026

First published on Enterprise IT World. Authored by Subroto Kumar Panda As we stand on the final day of 2025, reflecting on a year of dizzying

The Great Dissolve: Re-Engineering Enterprise Workflows for the 2026 AI Paradigm
Thought Leadership
Dec 19, 2025

First published on Express Computer. Authored by Subroto Kumar Panda The notification of the Digital Personal Data Protection (DPDP) Rules, 2025, marks

The DPDP: An 18-month compliance imperative for the C-suite